Gradalis' Vigil®: A Fully Personalized, Patient-Specific Cancer Immunotherapy For Ovarian Cancer, Hosted by Gradalis, Inc on October 3, 2022 at 1:00 PM ET

Gradalis' Vigil^®: A Fully Personalized, Patient-Specific Cancer Immunotherapy For Ovarian Cancer

Monday, October 3, 2022 | 1:00 PM EDT

Hosted by Gradalis, Inc

Join us for the Gradalis KOL Event, featuring oncology experts Rodney Rocconi, MD, FACOG, Infirmary Cancer Care & O’Neal Comprehensive Cancer Center, UAB, and John Nemunaitis, MD, Chief Scientific Officer, Gradalis, who will discuss the current treatment landscape for patients with ovarian cancer and unmet medical needs. Gradalis is developing Vigil^®, a novel, personalized cellular immunotherapy platform that is designed to decloak the full repertoire of a patient’s tumor neoantigens, reactivate the immune system, and summon key effector cells to deliver a durable clinical benefit.

Additionally, members of Gradalis’ leadership will discuss results from VITAL, a Phase 2b trial of Vigil^® as maintenance therapy for ovarian cancer patients and the clinical development path forward.

A live Q&A session will follow the presentations.

IMPORTANT INFORMATION

Registration information

You are required to register in advance for this event. For those who are unable to listen at this time, a replay of the call will be available by clicking here.

Q&A information

If you would like to ask a question during the live Q&A, please submit your request to questions@lifesciadvisors.com.

SPEAKER BIOGRAPHIES

Rodney Rocconi, MD

Rodney Rocconi currently serves dual roles in a partnership between the University at Alabama at Birmingham (UAB) and Infirmary Cancer Care (ICC) in Mobile, Alabama. In addition to being Professor of Gynecologic Oncology at UAB he holds leadership positions of Associate Director and Director of Research at ICC in Mobile, Alabama. He has presented research at over 200 national meetings and published over 120 peer-reviewed manuscripts. His research interests include genetic/molecular determinants of racial healthcare disparities in gynecologic malignancies as well as understanding the molecular mechanisms of chemoresistance in ovarian cancer. Dr. Rocconi has served as principal investigator in over 60 clinical trials with multiple early phase 1/2 investigator-initiated studies. He has been recognized for his work as a recipient of the Gynecologic Cancer Foundation Ovarian Cancer Research Award, the Gynecologic Oncology Group Young Investigator Research Award, and an invited Associate Member of the NCI Early Detection Research Network.

John Nemunaitis, MD

John Nemunaitis is the co-founder and Chief Scientific Officer of Gradalis, Inc. Over 30 years, he has led teams to translate innovative science into cancer treatment therapies at the Mary Crowley Foundation, academic centers like the Fred Hutchinson Cancer Center, and Gradalis. A recognized expert in his field, John has been involved in the design and execution of over 600 clinical trials across the major tumor types and overseen management of over 6500 patients in clinical trial. He has been an author in 493 peer-reviewed publications and participated in 72 government regulatory presentations (FDA, IND, RAC). Dr. Nemunaitis has been involved in 30 new product IND’s (15 first in human) and has 27 patents issued for targeted therapeutics across five patent families.

250 West 55th Street, Suite 3401

New York, NY 10019

E: info@lifescievents.com

This message contains confidential and proprietary information and is intended only for the individual named. If you are not the named addressee you should not disseminate, distribute or copy this e-mail. Please notify the sender immediately by e-mail if you have received this email by mistake and delete this email from your system. All market prices, data and other information contained in this email are not warranted as to completeness or accuracy and are subject to change without notice. Any comments or statements made herein do not necessarily reflect the views of LifeSci Advisors, LLC, its affiliates, subsidiaries or agents. The message is not intended as an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Before opening any attachments please check them for viruses and defects.